Company Encyclopedia
View More
name
Iovance Biotherapeautics
IOVA.US
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.
1.946 T
IOVA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking107/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-53.89%E
    • Profit Margin-158.78%E
    • Gross Margin42.96%B
  • Growth ScoreB
    • Revenue YoY175.62%A
    • Net Profit YoY3.02%C
    • Total Assets YoY-8.69%E
    • Net Assets YoY-9.20%D
  • Cash ScoreB
    • Cash Flow Margin-62.98%D
    • OCF YoY175.62%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreA
    • Gearing Ratio22.39%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Graf Finckenstein Acquires 6,247 Of Iovance Biotherapeutics Inc [IOVA]

    Graf Finckenstein, an officer of Iovance Biotherapeutics Inc, filed a Form 4 with the SEC on December 3, 2025, disclosing changes in ownership. He exercised 12,695 shares and surrendered 6,448 shares at $2.20 each to cover option exercise costs and tax liabilities. His ending holdings are 111,656 shares. This transaction highlights insider trading activities within the company.

    Reuters·
    US
    IOVA
    -0.45%
    Reuters·
    US
    IOVA
    -0.45%

    Officer Puri Acquires 3,002 Of Iovance Biotherapeutics Inc [IOVA]

    Puri Raj K, an officer of Iovance Biotherapeutics Inc, filed a Form 4 with the SEC on December 3, 2025, disclosing changes in ownership. On December 1, 2025, Puri exercised 5,469 shares at $0.00 and surrendered 2,467 shares at $2.23 to cover option exercise costs and/or tax liabilities. The ending holdings are 215,859 shares directly. The Washington Service provides insider trading analysis and data services.

    Reuters·
    US
    IOVA
    -0.45%
    Reuters·
    US
    IOVA
    -0.45%

    Iovance Biotherapeutics shares are trading higher after Barcays maintained an Overweight rating on the stock and raised its price target from $4 to $9.

    benzinga_article·
    US
    IOVA
    -0.45%
    benzinga_article·
    US
    IOVA
    -0.45%

    Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays

    Barclays analyst Etzer Darout maintained a Buy rating on Iovance Biotherapeutics with a $9.00 price target. Darout, a 5-star analyst, focuses on healthcare stocks. Iovance also received a Buy from TD Cowen's Tyler Van Buren, while TR | OpenAI reiterated a Hold rating. Darout has a 25.0% average return and a 56.94% success rate.

    Tip Ranks·
    US
    IOVA
    -0.45%
    Tip Ranks·
    US
    IOVA
    -0.45%

    Iovance Biotherapeutics Grants Stock Options to New Employees Under Amended Inducement Plan

    Iovance Biotherapeutics Inc. has granted inducement stock options to 11 new, non-executive employees, covering 164,900 shares of common stock. The options have an exercise price of $2.18 per share, matching the closing price on the grant date, November 20, 2025. The options vest over three years, with one-third vesting on the first anniversary of the start date and the remainder vesting quarterly over the next two years, contingent on continued employment.

    Reuters·
    US
    IOVA
    -0.45%
    Reuters·
    US
    IOVA
    -0.45%
    © 2025 Longbridge｜Disclaimer